Immunobiology of mesenchymal stem cells

S Ma¹, N Xie¹, W Li¹, B Yuan², Y Shi*¹,³ and Y Wang*,¹

Mesenchymal stem cells (MSCs) can be isolated from almost all tissues and effectively expanded in vitro. Although their true in situ properties and biological functions remain to be elucidated, these in vitro expanded cells have been shown to possess potential to differentiate into specific cell lineages. It is speculated that MSCs in situ have important roles in tissue cellular homeostasis by replacing dead or dysfunctional cells. Recent studies have demonstrated that in vitro expanded MSCs of various origins have great capacity to modulate immune responses and change the progression of different inflammatory diseases. As tissue injuries are often accompanied by inflammation, inflammatory factors may provide cues to mobilize MSCs to tissue sites with damage. Before carrying out tissue repair functions, MSCs first prepare the microenvironment by modulating inflammatory processes and releasing various growth factors in response to the inflammation status. In this review, we focus on the crosstalk between MSCs and immune responses and their potential clinical applications, especially in inflammatory diseases.

Cell Death and Differentiation (2014) 21, 216–225; doi:10.1038/cdd.2013.158; published online 1 November 2013

Facts

- The immunoregulatory properties and the tissue reparative functions of mesenchymal stem cells (MSCs) are induced by inflammatory cytokines.
- MSCs express immunosuppressive molecules and various growth factors that facilitate tissue repair and maintain immune homeostasis.
- The plasticity of immunoregulatory roles of MSCs is relied on the inflammatory status.

Open Questions

- How do MSCs benefit patients suffering from inflammatory diseases?
- Do MSCs always possess the immunosuppressive properties?
- Does the efficiency of MSC engraftment at the injured tissue sites determine the therapeutic effects of MSCs?

Properties of Mesenchymal Stem Cells

MSCs exist in almost all tissues, and have the capacity of self-renewal and the potential to differentiate into multiple cell types. Under certain physiological and experimental conditions, MSCs differentiate into specialized cells,¹ although to a lesser extent than embryonic stem cells (ES) and induced pluripotent stem cells (iPS). Nevertheless, their differentiation capacity has encouraged scientists and clinicians to seek suitable protocols to apply these cells to treat various diseases. Recently, several studies have demonstrated that MSCs can be activated and recruited to sites of tissue damage where they regenerate new tissues and repair the defects.

Stem cells bring new hope for the treatment of many diseases. The clinical use of ES or iPS cells, however, is hampered by their tendency to form teratomas, by allogeneic rejection problems and by ethical issues. In comparison with ES cells and iPS cells, MSCs are devoid of the ethical, teratomas-formation and histocompatibility issues. MSCs can be isolated from nervous tissue, adipose tissue, bone marrow, amniotic fluid, umbilical cord, placenta, menstrual blood and even dental pulps.²-⁵ Morphologically, MSCs have the appearance of fibroblasts. Although there is no specific marker that identifies MSCs, these cells do express certain patterns of surface markers. Because of their potent self-renewal capacity, MSCs can be passaged many times without significant alteration of their major properties.⁶ MSCs have the

¹Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences/Shanghai Jiao Tong University School of Medicine, 225 South Chongqing Road, Shanghai 200025, China; ²National Institutes for Food and Drug Control, No. 2 Tiantan Xili, Beijing 100050, China and ³Child Health Institute of New Jersey, Robert Wood Johnson Medical School, Rutgers, the State University of New Jersey, New Brunswick, New Jersey 08801, USA
*Corresponding authors: Y Shi or Y Wang, Key Laboratory of Stem Cell Biology, Institute of Health Sciences, Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences/Shanghai Jiao Tong University School of Medicine, 225 South Chongqing Road, Shanghai 200025, China. Tel: +86 21 63848329; E-mails: yufangshi@sibs.ac.cn or yingwang@sibs.ac.cn

Keywords: mesenchymal stem cells; inflammatory diseases; immunoregulation; nitric oxide; indoleamine 2; 3-dioxygenase; engraftment

Abbreviations: MSCs, mesenchymal stem cells; ES, embryonic stem cells; iPS, induced pluripotent stem cells; EGF, epidermal growth factor; FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; TGFB, transforming growth factor-β; VEGF, vascular endothelial growth factor; HGF, hepatocyte growth factor; IGF, insulin growth factor-1; Ang-1, angiopeptin-1; KGF, keratinocyte growth factor; SDF-1, stromal cell-derived factor-1; GVHD, graft versus host disease; SLE, systemic lupus erythematosus; iNOS, inducible nitric oxide synthase; NO, nitric oxide; PGE2, prostaglandin E2; LIF, leukemia inhibitory factor; DTH, delayed-type hypersensitivity; IDO, indoleamine 2,3-dioxygenase; TSG-6, tumor necrosis factor-inducible gene-6; HO-1, hemeoxygenase-1; G-CSF, granulocyte colony-stimulating factor; IBD, inflammatory bowel diseases; EAE, experimental autoimmune encephalomyelitis

Received 29.11.13; revised 03.10.13; accepted 04.10.13; Edited by R De Maria; published online 01.11.2013
potential to differentiate into several different cell types, such as adipocytes, chondrocytes, osteoblasts, myocytes and neurons (Figure 1). These criteria are used to define cultured MSCs, however, the exact anatomical locations of these cells in situ remain unclear. Experiments to track MSCs in vivo have revealed that these cells reside mostly close to blood vessels, a trait that is similar to pericytes. Pericytes in culture are similar to cultured MSCs in terms of their morphological features, cell surface markers as well as differentiation potential into osteoblasts, chondrocytes and adipocytes. However, not all pericytes have the unique properties of MSCs and not all MSCs are equivalent to pericytes. The key distinction is that pericytes locate strictly in the basement membrane of capillary and post capillary, whereas MSCs can be isolated from interstitial tissues and tissues surrounding arteries and veins. In addition, the proposed functions of pericytes are heterogenous and varied from regulating vessel stabilization to vascular integrity and tone, which are different from the functions of MSCs. MSCs are involved in many physiological and pathological processes, including cellular homeostasis maintenance, aging, tissue damage and inflammatory diseases. Although their differentiation potential is less broad than that of ES cells and iPS, MSCs, nevertheless, hold great promise for clinical applications. The most prominent therapeutic effect of MSCs is excreted through their immunoregulatory functions. The aim of this review is to elucidate the bidirectional regulatory interactions between MSCs and immune responses. We specifically emphasize recent reports of in vitro investigations and in vivo preclinical studies that reveal the mechanisms of this MSC-immune response interaction. We also discuss their implications for the clinical uses.

Communication between MSCs and Damaged Tissues

Because of their broad tissue distribution, multipotent differentiation capacity and well-established effects in preclinical and clinical studies, MSCs are believed to have critical roles in repairing damaged tissues. Tissue injury is always associated with the activation of immune/inflammatory cells, not only macrophages and neutrophils but also adaptive immune cells, including CD4 T cells, CD8 T cells and B cells, which are recruited by factors from apoptotic cells, necrotic cells, damaged microvasculature and stroma. Meanwhile, inflammatory mediators, such as TNF-α, IL-1β, free radicals, chemokines and leukotrienes, are often produced by phagocytes in response to damaged cells and spilled cell contents. Thus, these inflammatory molecules and immune cells, together with endothelial cells and fibroblasts, orchestrate changes in the microenvironment that result in the mobilization and differentiation of MSCs into stromal and/or replacement of damaged tissue cells. These MSCs can be tissue-resident or be recruited from the bone marrow. However, the mechanisms by which MSCs are mobilized and recruited to damaged sites are not known. In addition, how they survive and differentiate into distinct cell types is still not clear. Once MSCs have entered the microenvironment of injured tissues, many factors, including cytokines such as TNF-α, IL-1, IFN-γ, toxins of infectious agents and hypoxia can stimulate the release of many growth factors by MSCs, including epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), insulin growth factor-1 (IGF-1), angiopoietin-1 (Ang-1), keratinocyte growth factor (KGF) and stromal cell-derived factor-1 (SDF-1). These growth factors, in turn, promote the development of fibroblasts, endothelial cells and tissue progenitor cells, which carried out tissue regeneration and repair (Figure 1, Table 1).

The barrier function of the endothelial monolayer in the capillary bed is often broken down in damaged tissues, allowing the release of protein-rich plasma and some leukocytes from the blood. MSCs produce various factors, like Ang-1, VEGF, HGF, EGF, PDGF, FGF, KGF and TGF-β, which directly affect endothelial cells. These paracrine trophic factors are potentially important in maintaining endothelial integrity and promoting angiogenesis through their ability to regulate endothelial cell proliferation and extracellular matrix production, reduce endothelial permeability or prevent interactions between leukocytes and endothelial cells. Apart from angiogenesis mediated by endothelial cells, in response to such trophic factors, fibroblasts also have essential functions in maintaining tissue integrity and promoting wound healing through their secretion of extracellular matrix and matrix metalloproteinase. Some in vivo studies have suggested that growth factors secreted by MSCs can be applied to improve wound healing and recovery from myocardial infarction.

The long-term functional recovery of damaged tissue and organs is likely to depend on the differentiation of tissue-intrinsic progenitors or stem cells. Although engrafted stem cells can differentiate into tissue cells, they also produce growth factors, including stem cell factor (SCF), macrophage colony-stimulating factor (M-CSF), SDF-1, leukemia inhibitory factor (LIF), Ang-1 and many chemokines, that intrinsically trigger tissue repair. HGF, a well-demonstrated growth

![Figure 1](link)

**Figure 1** The properties of MSCs. MSCs can be isolated from various tissues including adipose, bone marrow, umbilical cord, muscle and tooth root. After in vitro expansion, MSCs can be defined by several characteristics. Morphologically, MSCs are fibroblast like. They also express a panel of markers: positive for Sca-1, CD105, CD73, CD29 and CD90, and negative for CD31, CD45 and CD11b. In addition, MSCs have the potential to differentiate into adipocytes, chondrocytes, osteoblasts and other cell types.
factor in MSC-based tissue repair, was recently shown to be effective in modulating endogenous neural cell remyelination for the enhancement of functional recovery in both experimental autoimmune encephalomyelitis (EAE) and spinal cord demyelination.34 Taken together, these observations demonstrate complex interactions that exist between MSCs and the damaged tissue during the tissue repair process. The multitude of paracrine factors produced by MSCs, which provoke tissue-resident progenitor cells or other relevant cells to initiate tissue repair, may explain the dramatic beneficial effects of MSCs on tissue repair, even in the absence of local MSC engraftment.34,35

Some tissue injuries, including those induced by chemical toxicity and trauma, are considered not immune cell-related; however, strong inflammation still occurs in these damaged tissues.36,37 Thus, better elucidation of the detailed mechanisms underlying the inflammation-modulated production of growth factors by MSCs will provide a better perspective for the clinical application of MSCs or their paracrine factors in tissue regeneration.

MSCs and Inflammation Niches

Besides the reparative functions of MSCs in inflammatory niches, the increasing evidences demonstrate that MSCs have potent immunomodulatory properties. For example, MSCs retain dendritic cells (DCs) in an immature state by inhibiting the expression of MHC class II, CD1-a, CD40, CD80 and CD86, and by suppressing proinflammatory cytokine production.38 TNF-a-stimulated MSCs can recruit more monocytes/macrophages to tumor site to formulate the immunosuppressive microenvironments, thereby enhancing tumor growth.39 Moreover, MSCs induce IL-10-secreting macrophages in both in vitro and in vivo study.40 Besides DCs and macrophages, NK cells can also be suppressed by MSCs through soluble factors, such as TGF-b and prostaglandin E2 (PGE2).41 Similar results are observed with human cells that MSCs inhibit IL-2- or IL-15-driven NK cell proliferation.42 In adaptive immune responses, MSCs have been already known to inhibit T-cell proliferation triggered by many

Table 1 Summary of growth factors critical for MSC-mediated tissue repair

| Growth factors | Roles in MSC-mediated tissue repair |
|----------------|------------------------------------|
| EGF            | Wound healing, tissue regeneration, neurogenesis |
| PDGF           | Tissue repair |
| FGF            | Tissue repair, intrinsic stem cell survival and regeneration |
| TGF-β          | Wound healing, angiogenesis, wound healing |
| VEGF           | Angiogenesis, wound healing |
| HGF            | Vasculogenesis, intrinsic neural cell regeneration |
| IGF-1          | Wound healing, neurogenesis |
| KGF            | Wound healing |
| Ang-1          | Angiogenesis, tissue repair |
| EPO            | Angiogenesis |
| GDNF           | Neuroprotective effect |
| SDF-1          | Neuroprotective effect, wound healing |
| IL-8           | Wound healing |

Abbreviations: Ang-1, angiopeptin-1; EGF, epidermal growth factor; EPO, erythropoietin; FGF, fibroblast growth factor; GDNF, glial cell line-derived neurotrophic factor; HGF, hepatocyte growth factor; IGF, insulin growth factor; IL-8, interleukin-8; KGF, keratinocyte growth factor; MSC, mesenchymal stem cell; PDGF, platelet-derived growth factor; SDF-1, stem cell-derived factor-1; TGF-β, transforming growth factor β; VEGF, vascular endothelial growth factor.
types of stimuli, to downregulate IFN-γ production and to induce Tr1 cells and Foxp3+ regulatory T cells. In addition, they can decrease B-cell proliferation by cell–cell contact and secreted soluble factor, although the effects change dramatically according to culture conditions. Recently, it has been suggested that immunosuppressive functions of MSCs are triggered by the surrounding microenvironment, where abundant inflammatory factors are released from immune cells. Initially, studies of the mechanism of immune modulation by MSCs were conflicting. Some studies of graft versus host disease (GvHD) and systemic lupus erythematosus (SLE) showed the benefits of MSCs in inhibiting vigorous immune responses in vivo. In other studies, although suppression of lymphocyte proliferation by MSCs could be observed in vitro, prolongation of graft survival and rescue from GvHD in vivo were not achieved. These investigations show that the immunosuppressive property of MSCs could be affected by specific disease-related tissue microenvironments. It has been reported that although allogeneic MSCs are rejected by the host immune system in MHC class I- and II-mismatched recipient mice, they exhibited similar therapeutic effect on EAE as that of autologous MSCs. That is, even though MSCs have the ability to downregulate immune responses, these cells may not be immune privileged. In MSC-based therapy, the dosage of cells is also important. Using a rat brain injury model, researchers recently have found that there is an efficacy plateau, above which additional delivered MSCs could not further improve the outcome. Moreover, MSCs with high passage number showed diminished stem cell activation and myocardial protection. Hence, immunosuppression by MSCs can be influenced by conditions, such as the source from which MSCs are isolated, the number of passages in culture before they are used, the dosages of MSCs administered and the specific pathological conditions of the recipients. Nevertheless, the immunomodulatory roles of MSCs have attracted great interest from basic and clinical researchers.

**Immunosuppressive Properties of MSCs**

Recently, our studies have found that the ability of MSCs to inhibit immune cell activity is licensed by inflammatory environment. IFN-γ in combination with one of the pro-inflammatory cytokines, TNF-α, IL-1α or IL-1β, can stimulate MSCs to elicit very high levels of immunosuppressive factors, as well as a burst of chemokine and adhesion molecule expression, including CXCR3 ligands, CCR5 ligands, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1). Their concerted action leads to an accumulation of immune cells in close proximity to MSCs, thus fabricating a microenvironment in which the effects of the locally acting factors produced by MSCs are amplified and leading to potent immunosuppression (Figure 3).

Surprisingly, the molecules that mediate MSC-induced immunosuppression are not the same in different species. We have found that murine MSCs use inducible nitric oxide synthase (iNOS) produced nitric oxide (NO), which is highly immunosuppressive at high concentrations through largely undefined mechanisms. In murine models of delayed-type hypersensitivity (DTH) and GvHD, when iNOS

---

**Figure 3** Immunosuppressive properties of MSCs. Damaged tissues are always accompanied by infiltration of immune cells and MSCs. Inflammation triggers the production of high levels of chemokines and adhesion molecules in MSCs, including CXCR3 ligands, CCR5 ligands, ICAM-1 and VCAM-1. These molecules induce the accumulation of immune cells in close association with MSCs, whereby high concentrations of NO (in murine MSCs) or depletion of tryptophan (in human MSCs) leads to the inhibition of immune cells. Other immunosuppressive factors such as IL-10, TSG6, IL-6, LIF, PGE2, HO-1 and truncated CCL2 could also affect immune cell activation, proliferation and functions.
activity was abolished in MSCs by either chemical inhibition or genetic ablation, the therapeutic effects disappeared.46,61,62 Meanwhile, iNOS-deficient MSCs also showed less therapeutic effects on autoimmune arthritis in mouse.63 These findings suggest that NO is a major player in mediating the immunosuppressive function of murine MSCs. Interestingly, metalloproteinase-mediated paracrine protection of CCL2 was also found to be important in murine MSC-based therapy on EAE.64

Of note, although murine MSCs use NO to exert their immunosuppressive function, human MSCs harness indoleamine 2,3-dioxygenase (IDO) instead.47,65,66 IDO is an enzyme that catalyzes the degradation of tryptophan, an essential amino acid, along the metabolic pathway to kynurenine. Immunosuppression is believed to result from the depletion of tryptophan and the accumulation of tryptophan metabolites locally,67 but their related mechanisms have not been fully investigated. Besides IDO, tumor necrosis factor-inducible gene-6 (TSG6), a supposedly anti-inflammatory protein, can be induced in human MSCs by TNF-α. Deletion of TS6G in human MSCs reverses their ability to repair myocardial infarct, corneal damage and fails to prolong the corneal allograft survival.68–70 In addition, TS6G production by human MSCs can ameliorate zymosan-induced mouse peritonitis by modulating the toll-like receptor 2 (TLR2)/nuclear factor-κB (NF-κB) signaling pathway in resident macrophages.71 However, the exact role of TS6G in human MSC-mediated immunoregulation merits further investigations. Other factors, such as HLA-G, LIF and some others, are also documented to mediate the immunosuppression by human MSCs in vitro.32,72,73 (Table 2). LIF was found to be secreted by mouse ES cell-derived neuron progenitors and exerts the therapeutic benefit to EAE,35 yet the role of this molecule in murine MSC-mediated immunoregulatory effects in remains elusive.

Studies implicated that, except above mentioned immunosuppressive factors in murine or human MSCs, some molecules are shared in murine MSC- and human MSC-mediated immunosuppression, such as PGE2, IL-10, hemeoxygenase-1 (HO-1), programmed cell death 1 ligand 1 (PD-L1) and IL-6.40,61,74–77 (Figure 3, Table 2). Particularly, PGE2 has been shown to be produced by inflammatory factor-stimulated murine and human MSCs. PGE2 released by mouse or human MSCs alone can reprogram macrophages to produce more IL-10, inhibit DC maturation as well as shift the balance between Th1 and Th2.40,74,75 Meanwhile, it is worth noting that, in presence of PGE2, the effects of IDO in MSC-mediated immunoregulation of T-cell proliferation and NK cell activation can also be enhanced.78,79 Additional studies of the mechanism of PGE2 expression in MSCs and its role in immunoregulation will be helpful for better clinical applications of MSCs. Soon after the discovery of the immunosuppressive function of MSCs, it was found that there was a clear relationship between IL-10 and the immunosuppressive behavior of MSCs. IL-10 production was found in vivo by MSC administration or in vitro when MSCs cocultured with splenocytes. However, the role of IL-10 is still controversial. Some studies indicate that MSCs alone or with LPS/IL-3 stimulation do not secret IL-10, whereas other studies suggested that MSCs could produce high levels of IL-10 when they are cocultured with activated lymphocytes.80–82 Thus, it is obscure that the increased IL-10 production is actually from MSCs or from immune cells cocultured with MSCs. However, it has been shown that IL-10 blockade did not affect MSC-mediated immunosuppression on lymphocytes.83 Clearly, further studies should illustrate detailed mechanisms of these inhibitory factors in MSC-based immunosuppressive functions, orchestrate the network of when, where and how MSCs implement its beneficial roles in clinical applications.

The immunosuppressive property is just one facet of MSC-mediated immunomodulation, however, the emerging evidence points out that MSCs can promote immune responses in the presence of low levels of inflammation,84 indicating the plasticity

---

**Table 2** Summary of factors critical for MSC-mediated immunosuppression

| Immunomodulatory factors | Species | Roles in MSC-mediated immunosuppression |
|--------------------------|---------|----------------------------------------|
| iNOS                     | Murine MSCs | Inhibits T-cell proliferation<sup>48,61,62</sup> |
| CCL2                     | Murine MSCs | Inhibits T-cell proliferation<sup>47</sup> |
| IDO                      | Human MSCs | Inhibits T-cell proliferation<sup>132</sup>, impairs NK cell activity<sup>78</sup> |
| Semaphorin-3A            | Human MSCs | Inhibits T-cell proliferation<sup>133</sup> |
| B7-H4                    | Human MSCs | Inhibits T-cell activation and proliferation<sup>134</sup> |
| HLA-G                    | Human MSCs | Inhibits PBMC response<sup>21,135</sup> |
| LIF                      | Human MSCs | Inhibits T-cell proliferation<sup>132</sup> |
| TSG6                     | Human MSCs | Regulates macrophages<sup>71</sup>, inhibits inflammation<sup>136</sup> |
| Galectin(s)              | Human MSCs | Inhibits T-cell proliferation<sup>73,133</sup> |
| HO-1                     | Murine MSCs, human MSCs | Inhibits T-cell response<sup>61</sup> |
| IL-6                     | Murine MSCs, human MSCs | Induces IL-10<sup>1</sup> and TGF-β<sup>1</sup> |
| TGFB-β                   | Murine MSCs, human MSCs | Inhibits the differentiation of dendritic cells<sup>137</sup> |
| IL-10                    | Murine MSCs, human MSCs | Induces Th1 cells<sup>139</sup> |
| PGE2                     | Murine MSCs, human MSCs | Induces Foxp3<sup>1</sup>, inhibits NK cell function<sup>61</sup>, inhibits type II macrophages<sup>143</sup> |
| PD-L1/2                  | Murine MSCs, human MSCs | Inhibits T-cell responses decreases Th17 cell differentiation<sup>140,82,142</sup> |
| FasL                      | Murine MSCs, human MSCs | Induces Foxp3<sup>1</sup>, Tregs<sup>143</sup> |

Abbreviations: CCL2, chemokine ligand 2; DC, dendritic cells; FasL, Fas ligand; HLA-G, human leukocyte antigen G; HO-1, heme oxygenase-1; IDO, indoleamine 2,3-dioxygenase; iNOS, inducible nitric oxide synthase; LIF, leukemia inhibitory factor; MSCs, mesenchymal stem cells; PGE2, prostaglandin E2; PD-L1/2, programmed cell death 1 ligand1/2; PBMC, peripheral blood mononuclear cells; TSG6, TNF-α stimulated gene/protein 6
of the immunoregulatory functions of MSCs. When inflammation is low or the expression of the above mentioned immunosuppressive factors is inhibited, MSCs could dramatically promote immune responses (Figure 4). This conceptual change has significant implications for proper clinical application of MSCs.

Immune Enhancing Properties of MSCs

One of the early clinical studies of MSCs is to treat GvHD patients. However, the therapeutic effects are not always achieved. In some clinical trials, MSCs were ineffective in GvHD patients. In some cases, MSCs accelerated graft rejection, even coadministered with cyclosporine A (CsA). The question is why the immunosuppressive function of MSCs is not always achieved. Under certain conditions, indeed, the immunosuppressive function of MSCs does not occur, instead, an enhanced immune response is observed. For example, under inflammatory conditions rendered by high dose of concanavalin A (ConA) or proinflammatory cytokines, MSCs exerted strong immunosuppressive effect. However, with low dose of ConA or the addition of IL-10, the suppressive effect of MSCs was abrogated. This can also happen when the levels of inflammatory cytokines are insufficient to stimulate MSCs to secret enough NO, although still produced chemokines.

Previous experiment also indicated that vigorous inflammation is important in eliciting the immunosuppressive function of MSCs in vivo. Less protection to GvHD was observed if MSCs were administrated at the day of bone marrow transfer. Good therapeutic effect can be achieved when MSCs were infused after disease development. Therefore, the inflammation status determines the immunomodulatory tendency of MSCs. Notably, with low dose of IFN-γ, the antigen presentation ability could be induced in MSCs. In fact, IFN-γ-stimulated MSCs can be regarded as conditional antigen presenting cells. Antigen-pulsed IFN-γ-treated MSCs can induce antigen-specific cytotoxic CD8+ T cells in vivo and thereby making MSCs candidates for the treatment of cancer or infectious diseases. Thus, except immunosuppressive roles, MSCs could also upregulate immune responses. Further studies on the molecular mechanisms regulating the immunoregulatory property of MSCs could have dramatic impact on the clinical application of these unique cells.

Engraftment of MSCs at Sites of Injury or Inflammation

It has been reported that trophic factors produced by MSCs can be used to implement therapeutic effects to inflammatory diseases, whereas in damaged tissue engrafted MSCs can exert concerted action, orchestrating with immune cells.
sternal cells, endothelial cells and tissue progenitor cells to promote tissue repair.34,48 Hence, the successful engraftment of MSCs to inflammatory niches and sites of injury are important considerations when analyzing the beneficial effects of MSCs. Unlike the well-characterized phenomenon of leukocyte homing, the mechanism of MSC homing, by de novo or exogenously delivered MSCs, is still unclear. However, MSCs expressing sialyl Lewis(x), a molecule capable of promoting leukocyte migration in the inflamed tissue, exhibit higher efficiency in homing to inflamed tissues.96 It is important to note that the peripheral blood of irradiated NOD/SCID mice and allows easier hematological engraftment of MSCs as well as possible reinfusion. In addition, MSCs may be expanded in vitro and passaged in culture. However, MSCs may have expanded and homed to sites of injury in situ. It has been reported previously that MSCs expanded in culture underwent hypoxic stimulation or protection in ischemia/reperfusion, a phenomenon associated with reduced growth factor production by MSCs with high passage numbers.95,96 Besides, MSCs can acquire or lose certain surface receptors during culture, which might affect their chemotaxis ability.98 Indeed, compared with freshly isolated MSCs, cells maintained in culture display impaired homing ability.98,99 Related to this, CXCR4, a receptor for SDF-1, is present at high levels in the bone marrow and ischemic tissues, always decreases from the surface of MSCs after culture. However, hypoxic culture condition can promote MSC engraftment through enhancing CXCR4 and CX3CR1 expression.100 In addition, when cultured MSCs are treated with a panel of cytokines, CXCR4 level can also be recovered. This effect helps to promote the bone marrow engraftment of MSCs in irradiated NOD/SCID mice and allows easier hematological recovery of transplanted MSCs.101 Moreover, TNF-α, TGF-β and IL-1β can stimulate MSCs to secret high levels of matrix metalloproteinase, which can endow these cells the ability to migrate through extracellular matrix in response to chemokines.102 Furthermore, in in vivo study, pretreating MSCs with TNF-α or a cocktail of cytokines resulted in enhanced MSC engraftment efficiency and improvement in acute pyelonephritis.103. Thus, many factors can influence MSC mobilization and engraftment. Therefore, it is critical to accurately assess and tightly control the properties of cultured MSCs for clinical application; otherwise, the physiological microenvironments they encounter may cause them to behave in unexpected ways.

Therapeutic effects of MSCs that are depending on the specific disease status. The various routes of injection that have been tried, including intravenous, intraperitoneal, intra-arterial and in situ, each affects the efficiency of MSC homing or localization to target organs.98 Among them, intravenous delivery is convenient and successful in treating certain type of diseases, but better engraftment efficiency can sometimes be obtained by intra-arterial and in situ injections, such as myocardial infarction, kidney transplantation and brain injury.104–107 Administration of MSCs in situ, although highly sometimes effective in both engraftment and therapy, is less clinically applicable as it is so invasive and introduces cells in a microenvironment that could be unsuitable for survival.108 In another study, in spinal cord injury, intravenous transplantation was more effective in promoting the survival of cerebellar Purkinje cells and MSC engraftment than that of intracranial injection.109 The intraperitoneal injection route has been rarely used, but some recent studies used it to treat muscular dystrophy and IBM in the mouse model, resulting in effective engraftment and therapeutic effects.110–112 Therefore, when MSCs are used to treat distinct diseases, their administration routes should be well-selected. Another influence on MSC effectiveness is the stage of disease: delivery of MSCs at an early stage following an event causing ischemia or EAE has shown enhanced engraftment rates or therapeutic effects, whereas administrated at the relapse stage of EAE, their beneficial effects are reduced.64,93,113 Finally, the dose of MSC administration should also be considered, because more MSC administration does not show a better therapeutic effect in the brain injury animal model.55 Taken together, these studies clearly demonstrate that when MSC-based therapies are used in preclinical experiments and clinical trials, the source of MSCs, the dose, route and timing of MSC administration should all be carefully considered.

Conclusions
We have highlighted the current understanding of the interaction between MSCs and immune responses. The differences, between murine MSCs and human MSCs, in the mechanisms mediating immunosuppression were discussed. As IDO is so central to the immunoregulatory function of human MSCs, the precise roles of tryptophan depletion and tryptophan metabolites in orchestrating such immunosuppression merit further investigation. Although MSCs disappear quickly after administration, their immunosuppressive effects linger for considerably longer. Considering that MSC supernatant alone can be effective in treating some diseases, it is possible that MSCs themselves may not be indispensable in mediating the therapeutic effect. In other words, is MSC differentiation-based repair sufficient for disease treatment, or do MSC-produced factors that modify the tissue microenvironment and lead to recovery intrinsically. Efforts of scientists in the coming years are anticipated to elucidate the precise roles of MSCs, both their reparative and immunoregulatory functions, and the mechanisms that impart and govern their clinical efficacy in the treatment of disease.

Conflict of Interest
The authors declare no conflict of interest.
Acknowledgements. This work was supported by grants from the Ministry of Science and Technology of China (2010CB945600 and 2011DFA30630), Scientific Innovation Project of the Chinese Academy of Science (XDA 01040107 and XDA 01040110), Projects of International Cooperation and Exchanges NSFC (3101030908), the General Program of NSFC (81273316), Shanghai municipal Nature Science Foundation (12ZR1452800), the Knowledge Innovation Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (2012KIP202) and Innovation Program of Shanghai Municipal Education Commission (13YZ7029). We gratefully acknowledge the support of SA-SIBS Scholarship Program.

1. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Rev Immunol 2008; 8: 725–762.

2. Portmann-Lanz CB, Schoebberlein A, Huber A, Sager R, Malek A, Holzgreve W et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol 2006; 194: 664–673.

3. Musina RA, Belyavski AV, Tarusova OV, Panasyuk AF, Keiliss-Borok IV. Stromal-derived factor-1 in the human endometrium. Cell Immunol 2008; 259: 152–155.

4. Steigman SA, Fauza DO. Isolation of mesenchymal stem cells from amniotic fluid and bone marrow. Cells Tissues Organs 2003; 174: 107–109.

5. Mackay AM, Beck SC, Murphy BM, Barry FP, Chichester CG, Pittenger MF. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng 1998; 4: 415–428.

6. Tintin V, Paino F, d’Aguino R, Desiderio V, De Rosa A, Papaoccio G. Methods for the identification, characterization and banking of human DPSCs: current strategies and perspectives. Stem Cell Rev 2011; 7: 658–655.

7. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 144–147.

8. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Rev Immunol 2008; 8: 725–762.

9. Portmann-Lanz CB, Schoebberlein A, Huber A, Sager R, Malek A, Holzgreve W et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol 2006; 194: 664–673.

10. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Rev Immunol 2008; 8: 725–762.

11. Portmann-Lanz CB, Schoebberlein A, Huber A, Sager R, Malek A, Holzgreve W et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol 2006; 194: 664–673.

12. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Rev Immunol 2008; 8: 725–762.

13. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS et al. Mesenchymal stem cells secrete angiogenic and immunomodulatory factors that promote vascular and neural regeneration. Cell 2006; 125: 305–313.

14. Hirschi KK, D’Amore PA. Pericytes in the microvasculature. Curr Protoc Stem Cell Biol 2008; e1E.2.1–e1E.2.12.

15. Tintin V, Paino F, d’Aguino R, Desiderio V, De Rosa A, Papaoccio G. Methods for the identification, characterization and banking of human DPSCs: current strategies and perspectives. Stem Cell Rev 2011; 7: 658–655.

16. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissue. Cytology 1977; 17: 331–340.

17. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 144–147.

18. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Rev Immunol 2008; 8: 725–762.

19. Portmann-Lanz CB, Schoebberlein A, Huber A, Sager R, Malek A, Holzgreve W et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol 2006; 194: 664–673.

20. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Rev Immunol 2008; 8: 725–762.

21. Portmann-Lanz CB, Schoebberlein A, Huber A, Sager R, Malek A, Holzgreve W et al. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neuroregeneration. Am J Obstet Gynecol 2006; 194: 664–673.

22. Shi Y, Su J, Roberts AI, Shou P, Rabson AB, Ren G. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 2012; 33: 136–143.

23. Mas XL, Liu KD, FC, Jiang XM, Jiang L, Li HL. Human mesenchymal stem cells increases expression of α-tubulin and angiopoietin 1 and 2 in focal cerebral ischemia and reperfusion. Curr Neurovasc Res 2013; 10: 103–111.

24. Aguilar S, Scotton CJ, McInty K, Nye E, Stamp G, Laurent G et al. Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One 2009; 4: e8013.

25. Hung SP, Yang MH, Tseng KF, Lee OK. Hypoxia-induced secretion of TGF-β/RIA in mesenchymal stem cell promotes breast cancer cell progression. Cell Transplant 2012; 21: 1869–1882.
51. Inoue S, Popp FC, Koshli GE, Piso P, Schmitt HJ, Geisler EK et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006; 81: 1589–1595.

52. Sudres M, Norol F, Tranando A, Gregoire S, Charlotte F, Levacher B et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 2006; 176: 7761–7767.

53. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I and class II-mismatched recipient mice. Blood 2005; 106: 4057–4065.

54. Rafie M, Birman E, Forner K, Galipeau J. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther 2009; 17: 1799–1803.

55. Wu J, Sun Z, Sun HS, Weisel RD, Keating A, Li ZH et al. Intravenously administered bone marrow cells migrate to damaged brain tissue and improve neural function in ischaemic lung. J Thorac 2008; 16: 993–1005.

56. Cristosanto PR, Wang M, Wairaku GM, Morrel ED, Terrell AR, Seshadri P et al. High passage number of stem cells adversely affects stem cell activation and myocardial protection. Shock 2006; 26: 575–580.

57. Ren G, Zhao X, Zhang L, Zhang J, L’Huillier A, Ling W et al. Inflammatory cytokines induce macrophage adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells for critical immunosuppression. J Immunol 2010; 184: 2321–2328.

58. Blesson S, Thiery J, Gaudin C, Thiery J, Gorringe MC, et al. Analysis of the mechanisms of human cytotoxic T lymphocyte response inhibition by NO. Int Immunol 2002; 14: 1191–1197.

59. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2: 907–916.

60. Staykova MA, Bieren LA, Cowden WB, Willenborg DO, Crouch M. Nitric oxide induces polarization of actin in encephalitogenic T cells and inhibits their in vitro trans-endothelial migration in a 70S6 kinase-independent manner. FASEB J 2003; 17: 1337–1349.

61. Chabannes D, Hill M, Merleau E, Rossignol J, Brion R, Souliou JP et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007; 110: 3691–3694.

62. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 229–234.

63. Bouti C, Bony C, Courties G, Jergensen C, Noël D. IL-6-dependent PG-E2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 2015; 10: e14277.

64. Rafie M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 T cell-induced T cell and in a CC chemokine ligand 2-dependent manner. J Immunol 2009; 182: 5994–6002.

65. Kociker M, Angeli R, Pasini A, Lotto F, Andreoni A et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2008; 26: 386–398.

66. Mesias R, Zibert A, Duhov M, Goehr B, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103: 4613–4621.

67. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762–774.

68. Lee RH, Pulin AA, See MJ, Kota DJ, Ylostalo J, Larson BL et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in vivo. Blood 2006; 108: 4811–4824.

69. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815–1822.

70. Spaggiari GM, Abdoulrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MHC-derived prostaglandin E2. Blood 2009; 113: 6576–6583.

71. Raffa M, Teng Teo GS. Mesenchymal stem cell homing: the devil is in the details. J Pathol 2012; 228: 213–2152.

72. Roddy GW, Oh JY, Lee RH, Bartosh TJ, Yostalo J, Cole K et al. Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-alpha stimulated gene/protein B. Stem Cells 2011; 29: 1572–1579.

73. Chio H, Lee RH, Bahnazin N, Oh JY, Prokop DJ. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing Toll-like/NF-kappaB signaling in resident macrophages. Blood 2011; 118: 330–338.

74. Nasel A, Mathieu N, Chapel A, Frick J, Francais S, Mazurier C et al. Immunomodulatory effects of mesenchymal stem cells: involvement of ILA-G. Transplantation 2007; 84: 231–237.

75. Gieseke F, Böhringer J, Bussolari R, Domini H, Hardtgering R, Müller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 2010; 116: 3770–3779.

76. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815–1822.

77. Spaggiari GM, Abdoulrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MHC-derived prostaglandin E2. Blood 2009; 113: 6576–6583.
103. Muschler GF, Nakamoto C, Griffith LG. Engineering principles of clinical cell-based tissue engineering. J Bone Joint Surg Am 2004; 86-A: 1451–1558.

104. Zonta S, De Martino M, Bedino G, Piotti G, Rampino T, Gregorini M et al. Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells Dev 2010; 19: 1075–1079.

105. Freyman T, Polin G, Osman H, Crary J, Lu M, Cheng L. Bone marrow-derived stromal cells enhances skin wound healing of C57BL/6 mice exposed to ionizing radiation. J Cell Mol Med 2010; 14: 1584–1594.

106. Lu D, Li Y, Wang L, Chen J, Mahmood A, Chopp M. Intraarterial administration of marrow stromal cells in a rat model of traumatic brain injury. J Neurotrauma 2001; 18: 813–819.

107. Walczak P, Zhang J, Gilad AA, Kedziorek DA, Ruiz-Cabello J, Young RG et al. The therapeutic potential of bone marrow mesenchymal stem cells in inflammatory bowel disease. J Transplant 2010; 2010: 1–6.

108. Muschler GF, Nakamoto C, Griffith LG. Engineering principles of clinical cell-based tissue engineering. J Bone Joint Surg Am 2004; 86-A: 1451–1558.

109. Castelo-Branco MT, Soares ID, Lopes DV, Buongusto F, Martinusso CA, do Rosario A Jr et al. Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells Dev 2010; 19: 1075–1079.

110. Xue Q, Luan XY, Gu YZ, Wu HY, Zhang GB, Gu OH et al. The negative co-signaling molecule b7-1 is expressed by human bone marrow-derived mesenchymal stem cell and its Modulates its T-cell allostimulatory activity. Stem Cells Dev 2010; 19: 27–38.

111. Rizzo R, Campioni D, Stignani M, Melchioni L, Bagnara GP, Bonsi L et al. A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stem cells. Cytotherapy 2009; 11: 574–580.

112. Najar M, Rousas R, Racicov G, Boulker HI, Lewalle P, Meuleman N et al. Mesenchymal stem cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interferon-6. Cytotherapy 2009; 11: 570–583.

113. Taisso R, Ilenco C, Quarto R, Cancedda R, Caspi RR, Pennesi G. Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2012; 53: 786–793.

114. Plotnikov EY, Pulkova NV, Pevzner IB, Zorova LD, Morosanova MA et al. Mesenchymal stem cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. J Pharmacol Exp Ther 2012; 342: 149–157.

115. Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham JD, Bundoc VG et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA 2010; 107: 5652–5657.

116. Yang M, Li Q, Zhang L, Lin H, Hu J, Li D et al. Mesenchymal stem cells attenuate peritoneal injury through secretion of TGF-6. PLoS One 2012; 7: e43768.

117. Djouras F, Charbonnier LM, Bouffard C, Louis-Pierce P, Bony C, Apparailly F et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025–2032.

118. Tipnis S, Viswanathan C, Majumdar AS. Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of mesenchymal stem cell-derived TGF-beta. J Cell Biochem 2007; 104: 1541–1558.

119. Xu Q, Liu X, Cheng K, Yang R, Zhao RC et al. Human mesenchymal stem cells inhibit Th17 cell differentiation by IL-10 secretion. Exp Hematol 2012; 40: 761–770.

120. Patel SA, Meyer JR, Greco SJ, Corcoran KB, Bryant M, Rameshwar P. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived Galectin-1. Cancer Immunol Immunother 2010; 59: 5883–5894.

121. Hayashi Y, Tsuji S, Tsujii M, Nishida T, Ishii S, Iijima H et al. The therapeutic potential of bone marrow mesenchymal stem cells in inflammatory bowel disease. J Transplant 2010; 2010: 1–6.

122. Kwon DS, Gao X, Liu YB, Duhvashky DS, Denduky AL, Bansal M et al. Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J 2008; 5: 453–463.

123. Sordi V, Maloisa ML, Marchesi F, Mercalli A, Mezzi R, Giordano T et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005; 106: 419–427.

124. Wolose AL, Kemp K, Sun M, Wilkins A, Scolding NJ. Human bone marrow mesenchymal stem cells protect catecholaminergic and serotonic neuronal perikarya and transporter function from oxidative stress by the secretion of glial-derived neurotrophic factor. Brain Res 2012; 1431: 86–96.

125. Wang F, Yasuhara T, Shingo T, Kameda M, Tajiri N, Yuan WJ et al. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats; focusing on anti-inflammatory effects of stem cell-derived factor-Tnf-α. BMC Neurosci 2010; 11: 52.

126. Kallifatidis G, Groth A, Frommhold D, Apel A, Mattern J et al. Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells Dev 2010; 19: 1075–1079.

127. Najar M, Rousas R, Racicov G, Boulker HI, Lewalle P, Meuleman N et al. Mesenchymal stem cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interferon-6. Cytotherapy 2009; 11: 570–583.

128. Taisso R, Ilenco C, Quarto R, Cancedda R, Caspi RR, Pennesi G. Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2012; 53: 786–793.

129. Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham JD, Bundoc VG et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA 2010; 107: 5652–5657.

130. Patel SA, Meyer JR, Greco SJ, Corcoran KB, Bryant M, Rameshwar P. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Cell Biochem 2007; 104: 1541–1558.

131. Xu Q, Liu X, Cheng K, Yang R, Zhao RC et al. Human mesenchymal stem cells inhibit Th17 cell differentiation by IL-10 secretion. Exp Hematol 2012; 40: 761–770.

132. Tipnis S, Viswanathan C, Majumdar AS. Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol Cell Biol 2010; 88: 795–806.

133. Sheng H, Wang Y, Jin Y, Zhang Q, Zhang Y, Wang L et al. A critical role of IFN gamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 2010; 20: 945–957.

134. Akijima K, Chen C, Wang D, X, Qu C, Yamaza T et al. Mesenchymal stem cell-induced immunoregulation involves FAS-Igand-FAS-mediated T cell apoptosis. Cell Stem Cell 2012; 10: 544–555.